GENETIC ANALYSIS NK -60 (8V8) — Financial Flexibility Index
GENETIC ANALYSIS NK -60 (8V8) has a Financial Flexibility Index of -0.13x as of June 2026. Free cash flow of €-3.22 Million (operating CF €-4.52 Million minus capex €1.30 Million) represents 0% of total liabilities (€23.93 Million). Check total reinvestment intensity of GENETIC ANALYSIS NK -60 to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GENETIC ANALYSIS NK -60 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for GENETIC ANALYSIS NK -60 across 5 annual periods. For the full cash flow conversion analysis, see 8V8 cash flow metrics.
Annual Financial Flexibility Index for GENETIC ANALYSIS NK -60 (2021–2025)
Year-by-year free cash flow to debt coverage for GENETIC ANALYSIS NK -60. Explore cash flow to debt ratio of GENETIC ANALYSIS NK -60 to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.31x | €7.94 Million | €2.40 Million | €25.37 Million | ▲ +164.3% |
| 2024 | -0.49x | €-9.68 Million | €-11.62 Million | €19.88 Million | ▲ +37.0% |
| 2023 | -0.77x | €-16.59 Million | €-17.23 Million | €21.49 Million | ▲ +18.6% |
| 2022 | -0.95x | €-19.23 Million | €-19.46 Million | €20.28 Million | ▲ +57.9% |
| 2021 | -2.25x | €-25.66 Million | €-27.62 Million | €11.40 Million | — |